Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post‐authorization safety study
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5800 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Soulmaz Fazeli Farsani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global RWE Capability, Boehringer Ingelheim International GmbH, Ingelheim, Germany. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Pancreatitis, Glucosides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Purpose
This study was undertaken to evaluate the potential risk of acute pancreatitis with empagliflozin in patients with type 2 diabetes (T2D) newly initiating empagliflozin.
Methods
Data from two large US claims databases were analyzed in an observational study of patients with T2D receiving metformin who were newly prescribed empagliflozin versus sulfonylurea (SU). Because dipeptidyl peptidase‐4 inhibitors and glucagon‐like peptide‐1 receptor agonists have been associated with the risk of acute pancreatitis in some studies, patients on these agents were excluded. Using pooled analyses of data from the two databases (2014–2021), patients initiating empagliflozin were matched 1:1 within database to patients initiating SU using propensity scores (PS) that incorporated relevant demographic and clinical characteristics. Prespecified sensitivity analyses were performed for design parameters.
Results
The analyses identified 72 661 new users of empagliflozin and 422 018 new users of SUs, with both patient groups on concurrent metformin therapy. Baseline characteristics within treatment groups appeared to be similar across the 72 621 matched pairs. After mean follow‐up of ~6 months, incidence rates of acute pancreatitis in the pooled matched cohort were 10.30 (95% confidence interval [CI] 9.29–11.39) events per 1000 patient‐years (PY) for empagliflozin and 11.65 (95% CI 10.59–12.77) events per 1000 PY for SUs. On a background of metformin, patients newly initiating empagliflozin did not have an increased risk of acute pancreatitis compared with those initiating an SU (pooled PS matched hazard ratio 0.88 [0.76–1.02]) across 75621.42 PY of follow‐up.
Conclusions
The results of this voluntary post‐approval safety study provide additional evidence that the use of empagliflozin for the treatment of T2D is not associated with an increased risk of acute pancreatitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global RWE Capability, Boehringer Ingelheim International GmbH, Ingelheim, Germany.
- Real World Evidence and Patient Outcomes, CERobs Consulting, LLC, Wrightsville Beach, North Carolina, USA.
- Global Integrated Evidence, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
- Global Patient Safety and Pharmacovigilence, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
ORCID-Profile: Soulmaz Fazeli Farsani, Cynthia J Girman
Förderung
- Boehringer Ingelheim
- Eli Lilly and Company
Zitieren
APA
Fazeli Farsani, S., Iglay, K., Zhang, L., Niyonkuru, C., Nessralla, L., & Girman, C. J. (2024). Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post‐authorization safety study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5800
Vancouver
Fazeli Farsani S, Iglay K, Zhang L, Niyonkuru C, Nessralla L, Girman CJ. Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post‐authorization safety study. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5800
BibTeX
@article{FazeliFarsani2024,
author = {Fazeli Farsani, Soulmaz and Iglay, Kristy and Zhang, Ling and Niyonkuru, Christian and Nessralla, Laurieann and Girman, Cynthia J},
title = {Risk of acute pancreatitis among new users of empagliflozin compared to sulfonylureas in patients with type 2 diabetes: A post‐authorization safety study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5800}
}
EUVIMED